Amendments to the Claims

1. (Previously amended) A method of treating dermal lesions caused by venom-induced immune dysregulation, the method comprising applying a therapeutically effective amount of an immune response modifier compound selected from the group consisting of imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, imidazonaphthyridine amines, tetrahydroimidazonaphthyridine amines, oxazolopyridine amines, oxazoloquinoline amines, thiazolopyridine amines, thiazoloquinoline amines and 1,2-bridged imidazoquinoline amines to the site of the lesion.

2. (Original) The method of Claim 1 wherein the immune response modifier compound is a compound of Formula I



I

wherein

R_1 is selected from the group consisting of S and NR_3,

R_2 is selected from the group consisting of hydrogen, straight and branched chain alkyl containing one to six carbon atoms, and alkoxyalkyl wherein the alkoxy moiety contains one to four carbon atoms and the alkyl moiety contains one to four carbon atoms; and

R_3 is selected from the group consisting of straight and branched chain alkyl containing one to six carbon atoms and straight or branched chain hydroxy alkyl containing one to six carbon atoms; or a pharmaceutically acceptable salt thereof.

3. (Original) The method of Claim 2 wherein R_1 is NR_3.

4. (Original) The method of Claim 2 wherein R_1 is S.

5. (Original) The method of Claim 2 wherein R_2 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, and ethoxymethyl.

6. (Original) The method of Claim 2 wherein R_3 is selected from the group consisting of 2-methylpropyl and 2-hydroxy-2-methylpropyl.

7. (Original) The method of Claim 2 wherein the IRM compound is selected from the group consisting of 4-amino-2-ethoxymethyl-α,α-dimethyl-1*H*-imidazo[4,5-*c*]quinoline-1-ethanol, 1-(2-methylpropyl)-1*H*-imidazo[4,5-*c*]quinolin-4-amine, 2-methylthiazolo[4,5-*c*]quinolin-4-amine, 2-ethylthiazolo[4,5-*c*]quinolin-4-amine, 2-propylthiazolo[4,5-*c*]quinolin-4-amine and 2-butylthiazolo[4,5-*c*]quinolin-4-amine.

8. (Original) The method of Claim 1 wherein the immune response modifier compound is applied via a cream or a gel.

9. (Currently amended) The method of claim 1 wherein the site of the lesion comprises a spider bite ~~source of the venom-induced immune dysregulation is an arthropod~~.

10-13. (Canceled)

14. (Currently amended) A method of ~~preventing~~ inhibiting dermonecrosis caused by venom-induced immune dysregulation, the method comprising applying a therapeutically effective amount of an immune response modifier compound selected from the group consisting of imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, imidazonaphthyridine amines, tetrahydroimidazonaphthyridine amines, oxazolopyridine amines, oxazoloquinoline amines, thiazolopyridine amines, thiazoloquinoline amines and 1,2-bridged imidazoquinoline amines to the site of the venom-induced immune dysregulation.

15. (Original) The method of Claim 14 wherein the immune response modifier compound is a compound of Formula I



I

wherein

R_1 is selected from the group consisting of S and NR_3,

R_2 is selected from the group consisting of hydrogen, straight and branched chain alkyl containing one to six carbon atoms, and alkoxyalkyl wherein the alkoxy moiety contains one to four carbon atoms and the alkyl moiety contains one to four carbon atoms; and

R_3 is selected from the group consisting of straight and branched chain alkyl containing one to six carbon atoms and straight or branched chain hydroxy alkyl containing one to six carbon atoms; or a pharmaceutically acceptable salt thereof.

16. (Original) The method of Claim 15 wherein R_1 is NR_3.

17. (Original) The method of Claim 15 wherein R_1 is S.

18. (Original) The method of Claim 15 wherein R_2 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, and ethoxymethyl.

19. (Original) The method of Claim 15 wherein R_3 is selected from the group consisting of 2-methylpropyl and 2-hydroxy-2-methylpropyl.

20. (Original) The method of Claim 15 wherein the IRM compound is selected from the group consisting of 4-amino-2-ethoxymethyl-α,α-dimethyl-1*H*-imidazo[4,5-*c*]quinoline-1-ethanol, 1-(2-methylpropyl)-1*H*-imidazo[4,5-*c*]quinolin-4-amine, 2-methylthiazolo[4,5-*c*]quinolin-4-amine, 2-ethylthiazolo[4,5-*c*]quinolin-4-amine, 2-propylthiazolo[4,5-*c*]quinolin-4-amine and 2-butylthiazolo[4,5-*c*]quinolin-4-amine.

21. (Original) The method of Claim 14 wherein the immune response modifier compound is applied via a cream or a gel.

22. (Currently amended) The method of claim 14 wherein the site of the venom-induced immune dysregulation comprises a spider bite~~source of the venom-induced immune dysregulation is an arthropod~~.

23-26. (Canceled)